抑制B细胞发育基因是糖皮质激素治疗急性淋巴细胞白血病疗效的关键
该研究整合B-ALL对糖皮质激素的转录反应与下一代短发夹RNA筛选,鉴定参与细胞死亡的GC调控效应基因及影响地塞米松敏感性的基因。分析揭示GC广泛抑制B细胞发育基因且与治疗反应相关;抑制PI3Kδ(CAL-101/艾德拉尼布)可中断双负反馈环路,增强GC调控转录,协同杀伤高耐药B-ALL。
要点
- GC通过GR调控基因诱导白血病细胞死亡,效应基因与耐药机制尚不明确。
- GC广泛抑制B细胞发育基因,该抑制与治疗反应相关。
- PI3Kδ抑制剂CAL-101增强GC调控转录,协同杀伤高耐药B-ALL。
核心结论
- GC抑制B细胞发育基因是GC疗效的关键,抑制PI3Kδ可增强GC调控转录并协同杀伤高耐药B-ALL。
研究设计与样本
- 研究整合B-ALL对GC的转录反应与下一代短发夹RNA筛选,鉴定GC调控的效应基因及影响地塞米松敏感性的基因。
主要发现
- GC广泛抑制B细胞发育基因,该抑制与治疗反应相关。
- PI3Kδ抑制剂CAL-101(艾德拉尼布)中断双负反馈环路,增强GC调控转录,协同杀伤具有不同遗传背景的高耐药B-ALL。
临床怎么用
- 作者认为该工作鉴定了多种增强淋巴系特异性联合化疗的机会,有潜力克服治疗耐药,并为理解GC生物学及GR调控转录机制提供资源。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucocorticoids (GCs), including dexamethasone (dex), are a central component of combination chemotherapy for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL). GCs work by activating the GC receptor (GR), a ligand-induced transcription factor, which in turn regulates genes that induce leukemic cell death. Which GR-regulated genes are required for GC cytotoxicity, which pathways affect their regulation, and how resistance arises are not well understood. Here, we systematically integrate the transcriptional response of B-ALL to GCs with a next-generation short hairpin RNA screen to identify GC-regulated "effector" genes that contribute to cell death, as well as genes that affect the sensitivity of B-ALL cells to dex. This analysis reveals a pervasive role for GCs in suppression of B-cell development genes that is linked to therapeutic response. Inhibition of phosphatidylinositol 3-kinase δ (PI3Kδ), a linchpin in the pre-B-cell receptor and interleukin 7 receptor signaling pathways critical to B-cell development (with CAL-101 [idelalisib]), interrupts a double-negative feedback loop, enhancing GC-regulated transcription to synergistically kill even highly resistant B-ALL with diverse genetic backgrounds. This work not only identifies numerous opportunities for enhanced lymphoid-specific combination chemotherapies that have the potential to overcome treatment resistance, but is also a valuable resource for understanding GC biology and the mechanistic details of GR-regulated transcription.
引用
- Kruth KA, Fang M, Shelton DN, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. 2017. PMID: 28424165. doi:10.1182/blood-2017-02-766204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。